Exact Sciences falls after disappointing colorectal cancer test results

Exact Sciences EXAS.O falls 10% to $42.20 after blood colorectal cancer (CRC) test did not meet expectations in trial

Brokerage BTIG calls it a "worst case scenario"

This also overshadowed a strong beat and raise Q2

EXAS on Weds inked deal for exclusive rights to Freenome's blood-based screening CRC test, but analysts noted this excluded multi-cancer tests, which disappointed investors

At least six brokerages cut price targets

Shares of rival Guardant Health GH.O gain nearly 17%

Canaccord Genuity says GH's Shield test performance is a touch better than Freenome's test

EXAS stock down 27% YTD while GH has surged nearly 70%